Please enable JavaScript or talk to your local administrator to get JavaScript enabled.


Novel Approach to Facilitate Decisions in Patients w/ Muscle Invasive Bladder CA

Funder: National Cancer Institute

Funding period
USD 450 K
Funding amount
? DESCRIPTION (provided by applicant): Radical cystectomy (RC) is standard treatment for patients with muscle invasive bladder cancer (MIBC). Level I evidence in the form of two randomized clinical trials and a meta analysis have demonstrated an improvement in survival with the integration of neoadjuvant cisplatin based combination chemotherapy (NC). Yet, a recent population based study demonstrated that only 1.2% of patients receive NC. Barriers to NC uptake are a) a lack of a tool predicting survival benefits with neoadjuvant therapy; and b) lack of evidence based protocols to communicate complex data about the risks and benefits of such therapy. To address these issues, we have recently developed a model to predict survival in patients with MIBC treated with surgery based on commonly available pre operative variables. While such a model is the first critical step for decision making, there is a paucity o data on what type of information patients need to make a decision, along with how this individualized prognositic information would be best conveyed and integrated into the patient physician consultation process. Thus, the specific aims are: Specific Aim 1: To develop and refine a counseling protocol consisting of a web based risk prediction tool and two educational brochures, one for patients and one for physicians. Two focus groups (FG) will provide insights about MIBC survivors' information needs and preferences. 1 FG with physicians will explore barriers to recommending NC. An Internet survey with physicians through the Bladder Cancer Advocacy Network will identify additional barriers. Results will be incorporated in the content and layout of the educational brochures and the risk prediction tool. Usability of the risk prediction tool and content of the brochures will be evaluated by physicians (Urologists (n=5) and medical oncologists (n=5)) and patients (n = 10). Specific Aim 2a): To train urologists and oncologists in the use of the counseling protocol. During a 30 min training session, physicians will be introduced in the use of the risk prediction tool and the physician brochure and be educated about appropriate risk communication principles. Aim 2b) To evaluate acceptability and feasibility of the counseling protocol with physicians and MIBC survivors. Newly diagnosed MIBC patients eligible for NC (N = 36), recruited in equal numbers from two study sites (Mount Sinai & Duke University), will participate in the counseling protocol. Pre and post intervention measurements will assess patients' risk perception, satisfaction with patient physician communication, and decision making variables. The present research has the potential to significantly impact and change clinical practice through the integration of a structured risk communication protocol into the patient physician consultation. It is innovative, a it is the first of its kind to combine an evidence based risk prediction tool with patient educatin into a physician patient counseling protocol for patients with MIBC.
Similar projects All >
Sorted by: Start Date
Project list item
Quantifying Risk and Resilience (R2) among Patients with Bladder Cancer: A Novel Personalized, Comprehensive Risk Stratification Program

Bladder Cancer Advocacy Network to Sarah Psutka, Jonathan Wright, Daniel Lin, John Gore, Ryan O'Malley, Anne Browning, Florian Fintelmann

USD 50,000
2020 - 2021
Project list item
Understanding the Burden and Impact of Financial Toxicity in Bladder Cancer: A Mixed Methods Study of 2 Diverse Patient Populations

Bladder Cancer Advocacy Network to Sumeet Kaur Bhanvadia, Siamak Daneshmand, Reginald Tucker-Seeley

USD 50,000
2019 - 2020
Project list item
Targeting FGF in Bladder cancer after Neoadjuvant Immunotherapy and Surgery

American Association For Cancer Research to Joshua James Meeks

USD 25,000
2019 - 2020
Project list item
Biomarker-Based Tools for Treatment Response Decision Support of Bladder Cancer


USD 653,319
2019 - 2024
Project list item
Refined phenotyping and personalized targeting of muscle-invasive bladder cancer

Swiss National Science Foundation to Roland Seiler, Kiu Yan Charlotte Ng, Eugenio Zoni, Marianna Kruithof-de Julio, Martina Minoli, Franziska Singer, Federico La Manna, Vera Genitsch

USD 702,564
2019 - 2023



    1117 Public Health and Health Services

  • RCDC

    Behavioral and Social Science

  • RCDC


  • RCDC

    Clinical Research

  • RCDC

    Patient Safety

  • RCDC

    Urologic Diseases




    7.3 Management and decision making

  • Health Research Areas

    Health services & systems

  • Broad Research Areas

    Clinical Medicine and Science